B7981110 A Phase 3, randomized, double blind, placebo controlled study to investigate the safety and efficacy of ritlecitinib in adult and adolescent participants 12 years of age and older with moderate alopecia areata

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-526355-62-00

Enrollment

Registered

2026-10-26

Start date

Unknown

Completion date

Unknown

Last updated

2026-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate alopecia areata (AA)

Brief summary

SALT 0 at Week 24

Detailed description

• SALT ≤10 at Week 24 • SALT ≤5 at Week 24 • SALT75 (≥75% improvement in SALT from baseline (Day 1)) at Week 24 • SALT90 (≥90% improvement in SALT from baseline (Day 1)) at Week 24, CFB in SALT score at Weeks 8, 12, 18 and 24, PGI-C response, defined as a score of “Greatly improved” or “Moderately improved” at Week 24

Interventions

DRUGRitlecitinib tosilate

DRUGRitlecitinib Tosilate

DRUGPlacebo for pf-06651600 100 mg

DRUGPlacebo for pf-06651600 50 mg

Eligibility

Sex/Gender

All

Age

0 Years to No maximum

Design outcomes

Primary

Measure	Time frame
SALT 0 at Week 24	—

Secondary

Measure	Time frame
• SALT ≤10 at Week 24 • SALT ≤5 at Week 24 • SALT75 (≥75% improvement in SALT from baseline (Day 1)) at Week 24 • SALT90 (≥90% improvement in SALT from baseline (Day 1)) at Week 24, CFB in SALT score at Weeks 8, 12, 18 and 24, PGI-C response, defined as a score of “Greatly improved” or “Moderately improved” at Week 24	—

Outcome results

None listed

Source: EU CTIS · Data processed: Oct 27, 2026